Jump to content

PubMed RSS Feed - - Non-Obligatory Role of Prostaglandin D2 Receptor Subtype 1 in Rosacea: Laropripant in Comparison to a Placebo Did Not Alleviate th


rss

Recommended Posts

Non-Obligatory Role of Prostaglandin D2 Receptor Subtype 1 in Rosacea: Laropripant in Comparison to a Placebo Did Not Alleviate the symptoms of Erythematoelangiectaic Rosacea.

J Clin Pharmacol. 2014 Aug 20;

Authors: Krishna R, Guo Y, Schulz V, Cord-Cruz E, Smith S, Hair S, Nahm WK, Draelos ZD

Abstract
Erythematotelangiectatic rosacea shares facial flushing features with those seen after niacin. This study was performed to test the hypothesis whether prostaglandin D2 (PGD2) receptor subtype 1 antagonist (MK-0524) will improve the symptoms of rosacea. The purpose of this study was to evaluate the effect of MK-0524 100 mg administered once daily for 4 weeks on the signs and symptoms of erythematotelangiectatic rosacea. Subjects received MK-0524 100 mg once-daily (n = 30) or placebo (n = 30) for 4 weeks. The primary pharmacodynamics endpoint was change in Clinician's Erythema Assessment (CEA) score from Baseline to Week 4. The Patient Self-Assessment (PSA) was a secondary endpoint. MK-0524 was generally well tolerated in this study For the primary endpoint of change in CEA score from Baseline to Week 4, the least-squares mean of change from Baseline to Visit 4/Week 4 was -3.7 and -3.4 for placebo and MK 0524 (100 mg), respectively. The least-squares mean difference (placebo minus MK-0524) with 90% confidence interval of change in CEA score from Baseline to Visit 4/Week 4 was estimated as -0.3 (-1.6, 1.0). For the secondary endpoints, the least-squares mean difference (placebo minus MK-0524) with 90% confidence interval of change from Baseline to Visit 4/Week 4 was estimated as -0.7 (-7.7, 6.4) for PSA total score, -4.5 (-14.2, 5.3) for PSA emotion score, -1.3 (-7.8, 5.3) for PSA symptoms score, and 3.6 (-4.3, 11.4) for PSA functioning score. MK-0524 administered once daily for 4 weeks was generally well tolerated in this population of subjects with rosacea. However, there were no clinically meaningful changes in the primary endpoint of CEA given that the response to MK-0524 could not be differentiated from that to placebo. There was also no clinically meaningful change in the secondary endpoint, PSA. A DP1 antagonist is not likely to be effective in rosacea.

PMID: 25142778 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/25142778?dopt=Abstract = URL to article

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
×
×
  • Create New...

Important Information

Terms of Use